LUNG CANCER

In 2019, there were approximately 30,000 new cases of small cell lung cancer diagnosed in the United States with nearly all cases attributable to cigarette smoking.

At a live virtual event, Martin Dietrich, MD, PhD, discusses how to approach biopsies and molecular testing in coordination with pathologists and testing services for patients with non–small cell lung cancer.

The PRESERVE-001 study has shown efficacy from ONC-392, a new anti-CTLA-4 antibody, as a monotherapy in patients with non–small cell lung cancer and ovarian cancer.

An otherwise healthy 60-year-old White woman presented with a nonproductive cough. The patient's case was the topic of discussion during a recent Case-Based Roundtable event.

The additional of nivolumab to chemotherapy improved event-free surivial in patients with resectable non-small cell lung cancer, meeting the primary end point of the CheckMate 816 trial.

Until the CONFIRM results, no phase 3 trial had demonstrated improvement survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy.

An otherwise healthy 60-year-old White woman presented with a nonproductive cough. She was later diagnosed with advanced stage non–small cell lung cancer.

Nino Balanchivadze, MD, FACP, discusses the results of an analysis investigating renal toxicity in patients with nonsquamous non–small cell lung cancer in relation to the race of patients.

Herbert L. Duvivier, MD, JD, explores treatment options in the small cell lung cancer setting for Lung Cancer Awareness Month.

How an oncologist treats a patients with non–small cell lung cancer wit the available treatment options is largely dependent on the patient's PD-L1 status.

The trial is evaluating the safety and efficacy of taletrectinib in ROS1 NSCLC. Taletrectinib is a novel TKI.

During a Targeted Oncology Case-Based Roundtable event, Melissa L. Johnson, MD, director, discussed the case of 66-year-old man with non–small cell lung cancer.

During an interview,Raymond U. Osarogiagbon, MD, discussed long-term care and outcome disparities of lung cancer in the United States.

In an interview with Targeted Therapies in Oncology, Nicholas J. Robert, MD, discussed what the results to date of the MYLUNG study mean for patients with non–small cell lung cancer.

The phase CANOPY-1 study has missed its co primary end points, but signals observed in a non–small cell lung cancer subgroup warrant further investigation.

Data continue to support the use of RET inhibitors is patients with RET fusion-positive non–small cell lung cancer.

Following the FDA approval of sotorasib for the treatment of KRAS G12C-positive non–small cell lung cancer, there is a great deal of interest in the KRAS inhibitor and its potential benefit.

Small cell lung cancer is the most aggressive form of lung cancer and mostly occurs in smokers. Although the disease has proved to be sensitive to chemotherapy and radiation, responses are short and those who relapse have short survival.

In an interview with Targeted Oncology, Solange Peters, MD, discussed the significance of the 3-year follow-up analysis of the CheckMate 743 study of nivolumab/ipilimumab in mesothelioma.

Data from the phase 3 POSEIDON trial were presented during the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.

In a 73-year-old patient, a PET scan revealed activity in the left upper lobe mass, supraclavicular nodal areas, and liver lesions, and an MRI discovered 1 small asymptomatic brain lesion. This lead to a diagnosis of stage T3N3M1-IV extensive-stage small cell lung cancer.

A 59-year-old man with a history of smoking, hypertension, and osteoarthritis presented with chest pain, cough, and dyspnea.

In an interview with Targeted Oncology, Nino Balanchivadze, MD, FACP, discussed the toxicity profile of platinum pemetrexed with pembrolizumab in patients with nonsquamous NSCLC treated in the KEYNOTE-189 study and how demographics and clinical characteristics may impact treatment.

An otherwise healthy 60-year-old White woman presented with a nonproductive cough. She was was later diagnosed with NSCLC.

A 59-year-old White man presented with chest pain, cough, and dyspnea. The patient was diagnosed with poorly differentiated adenocarcinoma of the lung.